KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

OneSpan (OSPN) Research & Development (2016 - 2026)

OneSpan filings provide 17 years of Research & Development readings, the most recent being $9.1 million for Q1 2026.

  • Quarterly Research & Development rose 14.51% to $9.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $35.3 million through Mar 2026, up 10.01% year-over-year, with the annual reading at $34.2 million for FY2025, 5.34% up from the prior year.
  • Research & Development hit $9.1 million in Q1 2026 for OneSpan, up from $8.0 million in the prior quarter.
  • Across five years, Research & Development topped out at $12.1 million in Q1 2022 and bottomed at $7.5 million in Q3 2024.
  • Average Research & Development over 5 years is $9.2 million, with a median of $8.8 million recorded in 2025.
  • The largest annual shift saw Research & Development tumbled 30.52% in 2022 before it rose 16.77% in 2025.
  • OneSpan's Research & Development stood at $8.1 million in 2022, then increased by 7.31% to $8.7 million in 2023, then fell by 5.08% to $8.3 million in 2024, then dropped by 3.64% to $8.0 million in 2025, then increased by 13.65% to $9.1 million in 2026.
  • Per Business Quant, the three most recent readings for OSPN's Research & Development are $9.1 million (Q1 2026), $8.0 million (Q4 2025), and $8.8 million (Q3 2025).